Forest Labs, Janssen Sue Several Drug Makers Over Bystolic
March 14 2012 - 2:02PM
Dow Jones News
DOW JONES NEWSWIRES
Forest Laboratories Inc. (FRX) and Johnson & Johnson's (JNJ)
Janssen Pharmaceutica NV sued several drug makers over plans to
market generic versions of Forest's Bystolic hypertension drug,
citing an existing patent.
The lawsuit before the U.S. District Court in Delaware names
units of Amerigen Pharmaceuticals Inc., Glenmark Pharmaceuticals
Ltd. (532296.BY), Hetero USA Inc., Torrent Pharmaceuticals Ltd.
(500420.BY) and Watson Pharmaceuticals Inc. (WPI) as defendants.
The two drug makers also sued Alkem Laboratories Ltd. and Indchemie
Health Specialties Pvt. Ltd in Chicago's U.S. district court.
Forest's patent on the blood-pressure medication expires in
December 2021 after patent-term extension.
Shares of Forest were up 10 cents at $33.80 mid-Wednesday, in
line with the broader market. Johnson & Johnson was off 21
cents at $65.12.
-By Drew FitzGerald, Dow Jones Newswires; 212-416-2909;
Andrew.FitzGerald@dowjones.com
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Oct 2023 to Oct 2024